Key result
Pharmacological management of peripheral arterial disease focuses on reducing cardiovascular risk with antiplatelets and statins, and improving claudication symptoms with cilostazol.
Pharmacological management of peripheral arterial disease focuses on reducing cardiovascular risk through antiplatelets, statins, and risk factor control, alongside symptom relief with cilostazol and smoking cessation.
Affirms standard PAD pharmacotherapy in older adults; leaves open geriatric-specific efficacy and safety trials.
The prevalence of peripheral arterial disease is of concern in the older population because many of these individuals often have comorbid conditions (eg, hypertension, diabetes, dyslipidemia) commonly associated with the disease. The primary pharmacological management of these patients' health is to reduce their risk for cardiovascular morbidity and mortality, followed by decreasing their intermittent claudication symptoms. The cardiovascular reduction management includes the use of antiplatelet medication such as aspirin or clopidogrel, statin therapy, and optimal control of hypertension, diabetes, and dyslipidemia. Lower extremity symptom improvement is managed pharmacologically with the use of smoking cessation regimens in patients with peripheral arterial disease who smoke and by cilostazol drug therapy.
No takes yet. Share an insight, caveat, or question.
Akiyode et al. (2013) conducted a review in Peripheral arterial disease. Pharmacological management of peripheral arterial disease focuses on reducing cardiovascular risk with antiplatelets and statins, and improving claudication symptoms with cilostazol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: